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2 
ABSTRACT 25 
Here we analyze the genetic and molecular basis responsible for a very benign 26 
phenotype observed in a NF1 patient. Quantification of cells carrying the NF1 mutation 27 
in different samples derived from the three embryonic layers revealed mosaicism. 28 
Furthermore, the construction of a minigene with patient’s mutation (c.3198-314G>A) 29 
confirmed its benign nature due to the leakiness of the splicing mechanism that 30 
generated a proportion of correctly spliced transcripts. Hence, we concluded that the 31 
mild phenotype observed in this patient is the result of the presence of mosaicism 32 
together with the benign nature of a leaky NF1-splice mutation. Finally, with the aim of 33 
developing a personalized therapeutic approach for this patient, we demonstrated 34 
correction of the splicing defect by using specific antisense morpholino oligomers. Our 35 
results provide an example of the molecular complexity behind disease phenotypes 36 
and highlight the importance of using comprehensive genetic approaches to better 37 
assess phenotype-genotype correlations. 38 
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3 
Neurofibromatosis type 1 (NF1; MIM#162200) is an autosomal dominant disorder 39 
characterized by an increased predisposition to develop certain types of malignancies 40 
as well as by the presence of a wide range of clinical traits involving cells of neural 41 
crest origin (reviewed in Riccardi, 1992). NF1 is caused by germline mutations in the 42 
NF1 gene, which is one of the human genes with a higher mutation rate. 43 
Comprehensive genetic studies identified more than 1,100 disease-causing mutations 44 
allowing a precise depiction of the NF1 germline mutational spectrum (reviewed in 45 
Messiaen, 2008). So far, two constitutive NF1 mutations have been correlated with a 46 
particular NF1 phenotype. Individuals with type 1 NF1-deletions, which encompass 1.4 47 
Mb of genomic DNA [Kayes, et al., 1994; Lopez Correa, et al., 1999] and involve 48 
several other genes in addition to the NF1, are characterized by a severe phenotype, 49 
consisting of learning problems, dysmorphic features and a high number of dermal 50 
neurofibromas [Mautner, et al., 2010; Pasmant, et al., 2010]. By contrast, patients with 51 
the recurrent c.2970-2972 delAAT mutation seem to express a moderate phenotype 52 
characterized by the absence of dermal neurofibromas [Upadhyaya, et al., 2007]. 53 
It has been suggested that a proportion of the new mutations are actually 54 
somatic implying than some sporadic patients are mosaics for a NF1 mutation [Kehrer-55 
Sawatzki and Cooper, 2008; Zlotogora, 1993]. Depending on the stage during 56 
development of the occurrence of the mutation we can distinguish patients showing 57 
generalized mosaicism, segmental mosaicism and gonadal mosaicism [Ruggieri and 58 
Huson, 2001]. Generalized mosaicism cases exhibit typical symptoms of the disease in 59 
a mild generalized form, making them very difficult to distinguish from non-mosaic 60 
patients. Segmental manifestation show clinical manifestations limited to one or a few 61 
areas of the body [Crowe, et al., 1956; Moss and Green, 1994; Riccardi, 1982], this is a 62 
rare condition which occurs at around 1:36,000-40,000 individuals [Friedman JM, et al., 63 
1999 ; Ingordo, et al., 1995; Ruggieri and Polizzi, 2000; Wolkenstein, et al., 1995]. 64 
Gonadal mosaicism is confined to the germline and is extremely uncommon in NF1 65 
[Bottillo, et al., 2010; Lazaro, et al., 1994]. Identification of somatic mosaicism and 66 
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4 
assessment of tissues affected by the NF1 somatic mutation is difficult and represents 67 
a challenge because it is especially important for providing accurate genetic 68 
counselling to the patient. 69 
For several genetic conditions, genotype-phenotype studies have suggested the 70 
importance of mechanisms regulating splicing as modifiers of phenotype in carriers of 71 
splicing defects [Nissim-Rafinia and Kerem, 2005]. For instance, a leaky effect of some 72 
splicing mutations associated with the production of wild-type transcripts from mutated 73 
alleles has been described. In some cases this phenomenon has been associated with 74 
a mild phenotype [Beck, et al., 1999]. The high number and diversity of splicing 75 
mutations in the NF1 gene made it interesting to explore the occurrence of leakiness in 76 
the splicing mechanism and its putative relation to the severity of the disease. 77 
In this work we describe the molecular basis underlying the mild NF1 phenotype 78 
of a patient fulfilling the NIH-NF1 established diagnostic criteria. Written informed 79 
consent was obtained from the patient following our institutional review board approved 80 
protocol. The patient is a 34-year-old woman who is a sporadic case of the disease 81 
(Figure 1A, left panel) showing 20 café-au-lait spots on the trunk and upper extremities, 82 
mild scoliosis, axillary and submammary freckling, and presence of less than 50 83 
minuscule neurofibromas (a few millimeters in diameter) located on the trunk, which 84 
started to appear when she was 18 years old (Figure 1A, right panel). The patient does 85 
not have Lisch nodules, any dysmorphism or learning disability. The NF1-mutational 86 
analysis using DNA isolated from peripheral blood of the patient revealed a point 87 
mutation in intron 19a of the gene (c.3198-314G>A) (Supp. Table S1). This mutation is 88 
a deep intronic mutation that creates a new cryptic acceptor splice site that uses two 89 
different cryptic donor splice sites present in the wild-type sequence (Supp. Table S2), 90 
to generate two aberrantly spliced transcripts showing inclusion of two different cryptic 91 
exons (Figure 1B); both cryptic exons would generate the same putative truncated 92 
protein (p.Asp1067TrpfsX7). 93 
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5 
We investigated two possible biological mechanisms that could explain the mild 94 
phenotype of the patient: somatic mosaicism and presence of mild NF1-mutation. To 95 
explore mosaicism we used a quantitative approach, based on the analysis of a single 96 
nucleotide primer extension reaction (SNaPShot analysis), to determine the proportion 97 
of cells containing the mutated allele in a subset of samples representative of the three 98 
embryonic layers. As this NF1 mutation had never been described before in other 99 
patients, it was impossible to obtain genetic material representative of a bona fide 100 
heterozygous sample that could be used as a control for quantification. Hence, we 101 
generated artificial controls consisting of two plasmids; one containing the patient’s 102 
mutation and the other bearing the wild type sequence. A mixture of serial proportions 103 
of both plasmids was used to obtain a standard curve that allowed estimation of the 104 
proportion of mutant alleles present in the different tissues obtained from the patient 105 
(Supp. Figures S1 and S2). This analysis revealed that samples derived from the 106 
endoderm and mesoderm, such as uroepithelial cells and peripheral blood respectively, 107 
showed a proportion of mutant allele of around 50% (Figure 1C and Supp. Figure S3), 108 
indicating that all the cells from these tissues are carrying the mutation in 109 
heterozygosis. However, samples derived from the ectoderm, such as skin, buccal 110 
swab or hair roots, showed a mutant allele proportion lower than 50%, ranging from 111 
20% to 35%, suggesting that only a proportion of the cells of these tissues were 112 
carrying the NF1 mutation. Cells from saliva showed an intermediate value that was in 113 
agreement with its nature, consisting of a mixture of white blood cells (mesoderm) plus 114 
buccal epithelial cells (ectoderm). To validate our results and confirm that the observed 115 
different proportions of mutated and WT alleles in the SNaPShot analysis were 116 
reflecting a somatic mosaicism and were not caused by amplification artefacts due to 117 
the different nature and origin of DNAs analyzed, we performed a control SNaPShot 118 
analysis using a SNP unrelated to the disease in the same set of DNA samples. We 119 
studied SNP rs2075786 located in an intronic region of the hTERT gene, located on a 120 
different human chromosome and for which our patient was heterozygous. In this case, 121 
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6 
the proportion of both alleles was close to 50% in all tested DNA samples (Figure 1C 122 
and Supp. Figure S4), a result that reinforced the validity of our previous results 123 
observed in the SNaPShot analysis of the NF1 mutation. Taking all our results together 124 
we can conclude that the patient studied here is a case of a NF1 mosaicism as the NF1 125 
mutation is present in different proportions in different cell types. Hence, this NF1 126 
mutation may have occurred early during development; as cells derived from the three 127 
embryonic layers are carrying the mutation in contrast to cases of segmental 128 
mosaicism, where the proportion of mutated cells in non-neural crest derived tissues 129 
can often lie below the detection level of routine analysis [Maertens, et al., 2007]. 130 
Although several cases of mosaicism have been described for NF1, the role of 131 
mosaicism in NF1 is still scarcely analyzed and limited to few number of cases [Kehrer-132 
Sawatzki and Cooper, 2008]. The use of different methodological approaches with high 133 
sensitivity such as SNaPShot analysis or real time quantitative allele discrimination 134 
[Aretz, et al., 2007; Maertens, et al., 2006], together with the investigation of several 135 
different tissues in cases where a mild form of the disease is observed, will help to 136 
ascertain the role of somatic mosaicism in Neurofibromatosis type 1. 137 
Taking into consideration the embryological origin of the different tissues 138 
analyzed and the fact that the majority of NF1 traits have a neural crest-derived cell 139 
origin (reviewed in Raedt et al., 2008), we were surprised by the proportions of mutated 140 
cells identified, greater in tissues mainly derived from the endoderm or mesoderm and 141 
smaller in tissues derived form the ectoderm. We decided to further explore the 142 
complex mosaicism exhibited in this patient by performing an X-chromosome 143 
inactivation (XCI) assay in the same set of tissues [Allen, et al., 1992]. X-chromosome 144 
inactivation is a stochastic event that occurs in the early stages of embryonic 145 
development in female embryos [Lyon, 1961; Lyon, 1962]. If a genetic mutation occurs 146 
after this inactivation, one can perform an X-chromosome inactivation test in different 147 
tissues in order to ascertain whether any bias is observed in the proportion of 148 
inactivation in both X-chromosomes and compare these results to the proportion of 149 
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7 
cells carrying the given genetic mutation [Wang, et al., 2009]. In our case, 150 
determination of clonal expansion was based on the analysis of DNA methylation and 151 
CAG tandem repeats at the human androgen receptor locus (HUMARA) [Allen, et al., 152 
1992], located on chromosome X, in the same tissues were mutation analysis was 153 
performed (with the exceptions of skin and hair roots). The number of CAG repeats 154 
differentiated the parental X chromosomes and methylation status distinguished the 155 
active and inactive X chromosome. In the absence of proliferative differences 156 
(advantages or disadvantages) between NF1-mutated and non-mutated cells, 157 
completely random XCI would be expected to result in around 50% inactivation of each 158 
X chromosome in all tissues. By convention, mildly skewed XCI was defined by an 159 
allele ratio 80-90% skewed inactivation, and extremely skewed XCI was defined by an 160 
allele ratio >90% skewed inactivation [Beever, et al., 2003; Kimani, et al., 2007]. 161 
Interestingly, we observed skewed XCI in the case of peripheral blood, saliva and 162 
uroepithelial cells with ratios of 12:88; 15:85 and 10:90, respectively. None of the rest 163 
of tissues from the patient, or a subset of control blood DNA samples, showed skewed 164 
XCI (Figure 1D and Supp. Figure S5). Tissues carrying the highest proportion of 165 
mutated cells coincided with those exhibiting skewed XCI. Moreover, in all these 166 
tissues, the same X chromosome was predominantly inactivated, making it unlikely that 167 
this observed skewed X- inactivation was the result of a purely random process. These 168 
results suggest a proliferative advantage of certain cells carrying the NF1 mutation that 169 
results in higher proportions of both percentage of mutated cells and cells with skewed 170 
X chromosome inactivation. Consequently, these proliferative differences suggest that 171 
the observed proportions of mutated cells in the adult tissues analyzed in the present 172 
study do not reflect the initial percentage of mutated cells in the different embryonic cell 173 
layers. However these results have to be taken carefully as it has been reported that X-174 
inactivation ratios may vary between different tissues within one normal individual 175 
[Sharp, et al., 2000]. 176 
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8 
To investigate a second possible cause of the observed mild NF1 phenotype, 177 
the benign nature of the constitutional NF1 mutation, we analyzed and quantified the 178 
expression of mutant transcripts produced by the deep intronic NF1 mutation identified, 179 
exploring different tissues from the same patient. We analyzed any deviation from the 180 
expected 50:50 proportion of mutant versus normal transcripts, taking into 181 
consideration the proportion of mutated cells identified in the analysis of DNA from 182 
different tissues. The analysis of RNA from fresh tissues indicated, with a certain 183 
degree of variation between samples, a low proportion of mutated transcripts, ranging 184 
from 1.4% to 14.41% and none in the hair root sample (Figure 2A upper panel). The 185 
study of cell cultures (lymphocytes and fibroblasts) revealed a low proportion of 186 
mutated transcripts as well as the action of the nonsense-mediated mRNA decay 187 
(NMD) mechanism on mutated-mRNA, since puromycin treatment was able to increase 188 
the levels of mutant transcripts observed in both cell types (Figure 2A bottom panel). 189 
By comparing the proportion of mutated transcripts (Figure 2A) with the percentage of 190 
mutated DNA (Figure 1C) in the same tissues, it became clear that there was a 191 
reduction in the proportion of mutated RNA. An illustrative example was the analysis of 192 
lymphocyte cells that showed equal proportions of mutated and wild-type alleles at the 193 
DNA level. However the analysis of their transcriptional profile provides evidence of a 194 
much lower proportion of aberrantly spliced transcripts than the expected 50% (20% 195 
after puromycin treatment and less than 10% without this treatment). Altogether, the 196 
differences between observed and expected proportions of aberrantly spliced 197 
transcripts, even after avoiding NMD, suggested the possibility that wild-type 198 
transcripts were also produced from the mutated allele, resulting in a low proportion of 199 
abnormal transcripts. In order to confirm this hypothesis we also constructed a 200 
minigene carrying the mutated allele. The analysis of the transcripts generated by the 201 
minigene containing mutation c.3198-314G>A indicated the production of both mutated 202 
and wild-type transcripts, while the minigene encoding the normal sequence only 203 
produced normal transcripts (Figure 2B and Supp. Figure S6), confirming that the low 204 
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9 
proportion of mutant transcripts is due to the production of normal transcripts from the 205 
mutated allele due to leakiness of the splicing mechanism. Therefore, the particular 206 
benign nature of this NF1 mutation was possibly contributing to the mild phenotype 207 
observed in our patient, by acting as a hypomorphic allele rather than a null one. 208 
Finally, and with the aim of starting to design personalized therapeutic 209 
strategies for NF1 patients, three different specific AMOs blocking cryptic splice sites 210 
used by the mutation were designed (as previously reported) [Pros, et al., 2009]. AMOs 211 
were designed, synthesized, and purified by Gene Tools (Philomath, OR) and endo-212 
porter (GeneTools) was used to deliver AMOs into skin-derived fibroblasts from the 213 
patient. We observed that the three designed AMOs were able to reduce the levels of 214 
mutant transcripts although a complete correction was only observed when a 215 
combination of the three AMOs was used (Figure 2C upper panel) as has also been 216 
described in other genetic disorders [Gurvich, et al., 2008]. To confirm that this 217 
reduction was specific to the AMO designed we performed the same treatment but 218 
using an unspecific AMO, designed to block a donor splice site generated by a different 219 
mutation located in intron 3 of the NF1 gene. As expected, no effect on the proportion 220 
of mutant transcripts was observed when using an unspecific AMO. Furthermore, we 221 
observed that IVS19a-AMO donors 1 and 2 inhibit, in a specific manner, the two 222 
aberrant transcripts generated. IVS19a-AMO donor 1 preferentially inhibits aberrant 223 
transcript 1 (r.3197-3198ins3198-214-3198-312) whereas IVS19a-AMO donor 2 224 
preferentially inhibits aberrant transcript 2 (r.3197-3198ins3198-245-3198-312) (Supp. 225 
Figure S7). Finally, to confirm that correction of aberrant splicing by AMO treatment at 226 
RNA level had some effect at a functional level, we indirectly assessed neurofibromin 227 
function, by measuring levels of active Ras (Ras-GTP) as an indicator of neurofibromin 228 
GTPase activity. We treated primary fibroblast cultures carrying the deep intronic 229 
mutation firstly with one AMO blocking the newly created acceptor splice site and 230 
secondly with a combination of three AMOs that were designed to block all cryptic 231 
splice sites located at intron 19a. We found that levels of Ras-GTP were lower in 232 
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10 
fibroblasts treated with specific AMOs than in untreated fibroblast or in fibroblasts 233 
treated with an unspecific AMO (Figure 2C lower panel), in agreement with our 234 
previous results using cell lines derived from other NF1 patients carrying the same type 235 
of mutation [Pros, et al., 2009]. This decrease in active Ras levels suggests that AMO 236 
treatment was indeed restoring neurofibromin GTPase function. 237 
To conclude, in this report we are presenting a very illustrative case where a 238 
combination of different biological processes such as somatic mosaicism and the leaky 239 
nature of a splicing mutation, are the possible causes of the mild NF1 phenotype 240 
observed in our patient. Our results highlight the complexity of genotype-phenotype 241 
correlations and the importance of performing comprehensive genetic studies to 242 
interpret clinical findings and facilitate genetic counselling. 243 
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Figure Legends 370 
Figure 1 371 
Patient and mutation description, SNaPshot results and XCI assay. A: Pedigree of the 372 
patient (Left panel). Detail of neurofibromas from the back where the small size of them 373 
can be appreciated (Right panel). B: Schematic representation of the NF1 deep 374 
intronic mutation (c.3198-314G>A) and the observed aberrant splicing. Constitutive 375 
and cryptic exons are represented by dark and light grey boxes, respectively. Mutated 376 
nucleotide is shown in capital letter and indicated by an arrow. Intron sequences are in 377 
lower case; boxes in introns mark cryptic splice sites. C: Summary of the SNaPShot 378 
results for mutation c.3198-314G>A (light grey bars) and the SNP rs2075786 (control 379 
SNP) (dark grey bars) in a battery of different samples from our patient. Allele 380 
proportion is indicated on the Y-axis, experiments were performed in triplicate. Data are 381 
represented by a bar consisting of the mean±SD. D: Summary of the X-chromosome 382 
inactivation assay from different tissues of the studied patient and controls. Results 383 
were averaged from at least two replicates of the experiment. 384 
Figure 2 385 
Quantification of transcripts, minigene assay and AMO treatment. A: RT-PCR analysis 386 
of total RNA was performed using specific primers to analyze the three types of 387 
transcripts produced (wild-type and two aberrant transcripts). The Y-axis of each graph 388 
shows the proportion of aberrant transcripts versus the total. Results are represented 389 
by a bar consisting of the mean for at least three independent experiments. Upper 390 
panel: Results from fresh tissues. Lower panel: Results from cultured lymphocytes and 391 
fibroblasts. P: Puromycin. B: Results of the RT-PCR analysis of the two constructed 392 
minigenes. MUT: corresponds to the minigene carrying mutation c.3198-314A; WT: 393 
correspond to the minigene with the normal sequence (c.3198-314G); C-: negative 394 
control. C: Correction of NF1 aberrant splicing and restoration of the neurofibromin 395 
function by AMOs. Upper panel: RT-PCR analysis shows the proportion of aberrant 396 
transcripts versus the total in the Y-axis. Results are represented by a bar consisting of 397 
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the mean±SD for at least three independent experiments. C1: Control, untreated cells 398 
from the patient; A: AMO blocking acceptor splice site , D1: AMO blocking Donor 1 399 
splice site , D2: AMO blocking Donor 2 splice site , A+D1+D2: Combined AMOs 400 
blocking the three splice sites, C2: unspecific AMO blocking a donor splice site created 401 
by a different mutation located in intron 3 of the NF1 gene. Bottom panel: Morpholino 402 
treatment shows reduction of Ras-GTP levels in fibroblast cell cultures from the patient. 403 
 404 
 405 
 406 
 407 
 408 
 409 
 410 
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MATERIALS AND METHODS 
Sample collection and DNA extraction 
Different samples belonging to tissues derived from the three embryonic layers were 
acquired from the studied patient. Skin biopsy, buccal epithelium and hair roots were 
acquired for ectoderm representation, peripheral blood and saliva for mesoderm, and 
urine samples to obtain uroepithelial cells detached from the bladder were collected for 
endoderm representation. Genomic DNA was extracted by using the Gentra purogene 
kit (Qiagen) except for the saliva, which was extracted by using the Oragene DNA 
(Genotek), following the manufacturer’s instructions. 
Mutation has been named according to the Human Genome Variation Society 
guidelines (http//:www.hgvs.org) and sequence variations checked by Mutalyzer – 
sequence variant nomenclature check V1.0.1. program 
(http//:www.LOVD.nl/mutalyzer/). The first nucleotide of the first methionine codon is 
denoted position +1 according to the NF1 mRNA sequence RefSeq NM_000267.2. 
Exons are not named consecutively but according to the accepted nomenclature used 
by researchers in the NF1 field. 
SNaPshot Analysis 
SNaPshot is a primer extension method based on the addition of a single dye-labelled 
dideoxy nucleotide to primers localized adjacent to the nucleotide under examination 
[Kaminsky, et al., 2005; Uhlmann, et al., 2002]. Primer sequences flanking the NF1 
mutation present in intron 19a and flanking an intronic SNP on chromosome 5 
(rs2075786) in the hTERT gene (human telomerase retrotranscriptase) were used, all 
primers are available upon request. Single nucleotide primer extension reaction was 
carried out with the SNaPshot Multiplex kit (Applied Biosystems) according to 
manufacturer’s instructions. Products were run in an ABI Prism 3130 DNA Sequencer 
and analyzed by GeneMapper v4.0 (Applied Biosystems). The degree of mosaicism 
was calculated using peak heights: Proportion of mutant allele A=A/(A+kG), where A 
was the peak height of the mutant allele, G the peak height of the wild type allele, and k 
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was a constant given by the ratio of A/G in heterozygous control samples. Three 
independent replicates of all experiments were obtained and in every experiment 
controls were included.  
Heterozygous control samples 
Artificial heterozygous control samples were created in order to simulate a patient with 
the same mutation studied in a non-mosaic state to obtain the constant necessary to 
estimate the proportion of the mutant allele in all the DNA samples studied. PCR 
products were amplified from the heterozygous patient, with the primers amplifying the 
studied mutation, and cloned into PCR 2.1 TOPO by the TOPO TA CLONING kit 
(Invitrogen). Purified constructs were used as homozygous wild type and mutant 
plasmids. The genotype of the two constructed plasmids was confirmed by DNA 
sequencing.  
X-chromosome inactivation assay 
We performed the human androgen-receptor X-inactivation assay as previously 
described [Allen, et al., 1992]. Briefly, 100 ng of each female genomic DNA sample 
was digested either with the methylation-sensitive restriction enzyme HpaII (New 
England Biolabs, Inc., Ipswich, MA) or incubated with 1× enzyme buffer only. Digestion 
was held for 16h at 37ºC and was then terminated by incubating the reaction at 65ºC 
for 20 min. From those reactions, one nanogram of each was then amplified by PCR 
with primers flanking the polymorphic androgen receptor CAG repeat. All reactions 
were performed at least in duplicate and primers are available upon request. PCR 
products were analyzed with ABI 3100 Genetics Analyzer (Applied Biosystems). The 
proportion of inactivation of the lower molecular weight allele (allele 1) was calculated 
using the following formula, which normalizes occasional biases in allele amplification: 
Proportion (allele 1) = ((d1/u1)/( d1/u1+d2/u2)) x 100, where d1 and d2 represent the two 
peak heights from the digested samples and u1 and u2 are the corresponding peaks 
from the undigested samples. Results were averaged from two replicates of the 
experiment. By convention, mildly skewed XCI was defined by an allele ratio >80-20% 
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and extremely skewed XCI was defined by an allele ratio >90-10% [Beever, et al., 
2003; Kimani, et al., 2007]. 
Cell lines and cultures 
For fibroblast isolation, skin was cut into small pieces and digested with 160 U/ml 
collagenase type 1 (Sigma, St. Louis, MO) and 0.8 U/ml dispase grade 1 (Roche 
Diagnostics, Penzberg, Germany [Serra, et al., 2001]. Fibroblasts were grown with 
Dulbecco’s modified Eagle’s medium (DMEM; Gibco, Invitrogen, Paisley, UK), 10% 
fetal bovine serum (FBS; Gibco, Invitrogen), and penicillin/streptomycin (Gibco, 
Invitrogen) at 37ºC and 5% CO2. 
RNA preparation, RT-PCR, and quantification of NF1 expression 
Total RNA was extracted by using the RNeasy Mini Kit (Qiagen, Heidelberg, Germany) 
following the manufacturer’s instructions after the addition of Puromycin (0.25mg/ml for 
4h) to prevent the nonsense mRNA decay mechanism (NMD). Reverse-transcription 
reactions were performed with random hexamers and SuperScript II Reverse 
Transcriptase (Invitrogen). PCR reactions were performed under the following 
conditions: 30 cycles of 94ºC for 30 sec, 60ºC for 30 sec, and 72ºC for 1 min after an 
initial denaturation of 3 min, and followed by a final extension of 8 min. Primer 
sequences used to amplify both wild-type transcripts and the different transcripts with 
cryptic exon inclusion are available upon request. PCR products were analyzed with 
the Agilent 2100 bioanalyzer with DNA 1000 LabChip kit series II (Agilent 
Technologies, Waldbronn, Germany). Percentages of cryptic exon inclusion were 
obtained by taking the sum of concentration values (nmol/l) of the different fragments 
(wild-type and aberrantly spliced) as 100%. 
Minigene constructs, transfection, and splicing analysis 
The NF1 minigene containing genomic sequence from exons 19a to 19b was created 
by cloning an amplified fragment of genomic NF1 into pcDNA3.1-TOPO (Invitrogen), 
primers are available upon request. 293-HEK Cells were transfected with 1 µg of 
plasmid by the use of Lipofectamine (Invitrogen). After 24h, cells were harvested and 
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RNA extracted using RNeasy kit (Qiagen). Semiquantitative amplification of spliced 
transcripts was carried out. 
Morpholino oligomer design and treatment 
The 25-mer AMOs were designed, synthesized, and purified by Gene Tools 
(Philomath, OR) and targeted the newly created aberrant acceptor splice site (AMO-
IVS19a A) and the two different silent donor splice sites (AMO-IVS19a D1 and D2). 
Endo-Porter (GeneTools) was used to deliver AMOs into cells. AMO sequences are 
available upon request. In this work we also used an unspecific AMO to evaluate the 
specificity of our designed AMOs. This unspecific AMO is designed to block a donor 
splice site generated by a mutation in intron 3 of the NF1 gene (c.288+2025T>G) [Pros, 
et al., 2009]. For fibroblast cell line treatment with AMOs, cells were seeded at 3x105 
cells/well, in a 6-well plate. The next day, culture medium was replaced by fresh 10% 
FBS/DMEM medium containing 20 µM of AMOs. Immediately afterwards, Endo-Porter 
was added and mixed well (6 mM). 
Ras-GTP assay and western blot of total Ras 
The Ras activation assay kit (Upstate Biotech, Lake Placid, NY) was used according to 
the manufacturer’s protocol. The assay uses affinity precipitation to isolate Ras-GTP 
from cell lysate. Fibroblast cell lysate (300 µg) was incubated with an agarose-bound 
Raf-1 RBD fusion protein. Agarose beads were collected by pulsing in a 
microcentrifuge (5 sec at 14,000 rpm, 3g), washed with lysis buffer, and resuspended 
in Laemmli sample buffer. Cell lysates containing 5 µg of protein were prepared for 
Western blot analysis of total Ras. Samples from the Ras-GTP assay and total Ras 
analysis were then boiled for 5 min and loaded onto 12% SDS-PAGE polyacrylamide 
gels. Samples were electrophoresed and transferred (400 mA) to a nitrocellulose 
membrane (Hybond-C extra, GE-Healthcare). The membrane was blocked with 5% 
non-fat dry milk and incubated overnight at 4ºC with primary antibody, anti-Ras clone 
RAS10 (1/300; Upstate Biotechnology, Lake Placid, NY) (1 µg/ml). This was followed 
by incubation with HRP-conjugated secondary antibody at room temperature for 1h. 
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The blot was developed using the West Pico SuperSignal substrate (Pierce) for the 
total Ras analysis and Tubulin and West Femto SuperSignal for the Ras-GTP assay. 
 
 
 
 
Page 23 of 33
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Supplementary Figure Legends 
Supp. Figure S1  
SNaPshot results from two different homozygous clones mixed to obtain different allele 
proportions. On the right of every SNaPshot graph the Sanger sequence is observed. 
The asterisk denotes the position of the mutation under examination. Numbers indicate 
the ratio between the wild type and mutant allele. 
Supp. Figure S2 
Regression analysis of SNaPshot analysis of c.3198-314G>A mutation after mixing two 
homozygous control cDNAs in different proportions. Allele proportions were calculated 
from the peak heights: Proportion of A allele= A/(A+kG) where the correction factor k is 
determined from the mix simulating an allele proportion of 0.5 (5:5). The measured 
allele frequencies were plotted against the expected allele frequencies. A near linear 
relationship over the whole data is confirmed (R2=0.998). 
Supp. Figure S3 
Results from SNaPShot analysis of c.3198-314G>A mutation in different samples. The 
asterisk denotes the position of the mutation under examination. 
Supp. Figure S4 
Results from SNaPShot analysis of rs 2075786 in different samples. The asterisk 
denotes the position of the mutation under examination. 
Supp. Figure S5 
Results from X-Chromosome Inactivation (XCI) Assay. A: Analysis of the XCI pattern in 
blood from four different controls. B: Analysis of the XCI pattern in different samples of 
the studied patient. U: undigested, D: digested. 
Supp. Figure S6 
Schematic representation of the wild type and mutant minigenes and their 
corresponding splicing. Solid line corresponds to the expected splicing, and dashed 
line corresponds to the wild-type splicing from the mutant allele that we are assessing 
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with this minigene analysis. E19a: Exon 19a, E19b: Exon 19b, I19a: Intron 19a, D1: 
Donor 1 cryptic splice site, D2: Donor 2 cryptic splice site. 
Supp. Figure S7 
Schematic representation of the three cryptic splice sites located deep inside intron 19a 
that allow the insertion of two aberrant transcripts: CEI1 and CEI2. And a graph 
showing the proportion of the two cryptic exon transcrits (CEI1 and CEI2); underneath 
the Agilent electrophoresis gel is shown. 
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Supp. Table S1: Description of the NF1 deep intronic mutation at genomic, mRNA and protein levels. 
 
 
Supp. Table S2: Summary of the predicted scores for the cryptic sites used by the identified mutation. 
 
  
3' splice-site (acceptor) sequences and scores 
 
 
5' splice-site (donor) sequences and scores 
 
 
DNA Mutation 
 
 
Sequence 
 
 
S&S 
 
 
NN 
 
 
ME 
 
 
MM 
 
 
Sequence 
 
 
S&S 
 
 
NN 
 
 
ME 
 
 
MM 
 
 
c.3198-314G>A 
 
 
(A) CAAATATTTTCAATCCATAG GTG mut 
 
 
84,57 
 
 
0,95 
 
 
9,05 
 
 
8,41 
 
 
(D1) AAG GTAGCC 
 
 
71,29 
 
 
0,8 
 
 
7,58 
 
 
5,31 
 
  
    CAAATATTTTCAATCCATGG GTG wt 
 
 
68,02 
 
 
0 
 
 
-22,81 
 
 
-16,3 
 
 
(D2) AAA GTAAGT 
 
 
87,84 
 
 
0,99 
 
 
9,72 
 
 
8,51 
 
 
Nucleotide introduced by mutation is in bold. Splice-site strength scores are obtained using the Shapiro and Senapathy (S&S) consensus splice-
site weight matrix, neural network (NN) prediction, first-order Markov models (MM), and a maximum entropy (ME) model. A higher score 
indicates a greater probability of the resulting sequence being used as a splice site. A: Acceptor splice site, D1: Donor 1 cryptic splice site, D2: 
Donor 2 cryptic splice site. 
DNA Mutation 
 
Intron 
 
 
mRNA effect 
 
 
Putative protein 
 
r.3197-3198ins3198-214-3198-312 c.3198-314G<A 19a 
r.3197-3198ins3198-245-3198-312 p.Asp1067Trp fsX7 
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Human Mutation
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41
42
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45
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